BETHESDA, Md., Oct. 4, 2011 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) (NORTHWEST BIO) today announced that it will be presenting at the second annual Cancer Immunotherapy: A Long-Awaited Reality Conference on Thursday, October 6, at the New York Academy of Medicine in New York City. The single-day conference unites key opinion leaders, industry executives, and other stakeholders to engage in discussions, exchange information, and highlight opportunities in the field of cancer immunotherapy that is now coming of age. Dr. Anthony Maida, COO, and Mr. Leslie J. Goldman, Sr. Vice President for Business Development, of NORTHWEST BIO will be making the presentation. They will be presenting the science of DCVax®, the promising clinical data generated to date, and the progress of the Company's pipeline of multiple individualized cancer vaccine products. They will indicate how NORTHWEST BIO's developing immunotherapy products hold the promise of treating cancers more effectively than the current standard of care, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the US and Europe. Ms. Linda Powers, CEO of NORTHWEST BIO said, "This topic and conference are particularly timely in view of yesterday's Nobel Prize in Medicine for certain key discoveries about the immune system – especially about the critical role of dendritic cells. At NORTHWEST BIO, we have developed medical treatments for cancer using these same dendritic cells, whose discovery by Dr. Ralph Steinman now has earned the Nobel Prize. Our medical treatments are one of the first personalized medicines to apply this potential: they make use of the patient's own dendritic cells, which are activated and "educated" to mobilize the immune system to attack that patient's particular cancer." "We have been developing these dendritic cell treatments for over a decade and have now reached late stage clinical trials," Ms. Powers continued. "In the trials so far, patients who received the DCVax® dendritic cell treatments lived for years longer than patients receiving standard of care (not just weeks or months longer), and without toxicity. Building upon the original discovery of dendritic cells by Dr. Steinman, we are working to make dendritic cell treatments widely available for patients, and believe that such treatments have the potential to become a new standard of care for most cancers."